About Scantox
Scantox is a company based in Lille Skensved (Denmark) founded in 1977.. Scantox has raised $6.29 million across 2 funding rounds. The company has 30 employees as of November 30, 2024. Scantox has completed 4 acquisitions, including Adlego Biomedical, Gentronix and Q&Q Labs. Scantox offers products and services including Discovery Services, Genetic Toxicology Services, Regulatory Toxicology Services, and Pharmaceutical Development Services. Scantox operates in a competitive market with competitors including Charles River Laboratories, LabCorp, Cytel, Precision Medicine Group and Veeda Clinical Research, among others.
- Headquarter Lille Skensved, Denmark
- Employees 30 as on 30 Nov, 2024
- Stage Minicorn
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Scantox Holding Aps
-
Annual Revenue
$18.22 M (USD)166as on Dec 31, 2022
-
Net Profit
$1.16 M (USD)71as on Dec 31, 2022
-
EBITDA
$1.45 M (USD)282as on Dec 31, 2022
-
Total Equity Funding
$6.29 M (USD)
in 2 rounds
-
Latest Funding Round
$228.85 K (USD), Unspecified
Jan 24, 2022
-
Investors
-
Employee Count
30
as on Nov 30, 2024
-
Investments & Acquisitions
Adlego Biomedical
& 3 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Scantox
Scantox offers a comprehensive portfolio of products and services, including Discovery Services, Genetic Toxicology Services, Regulatory Toxicology Services, and Pharmaceutical Development Services. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Specialized services for neurology-related drug discovery and efficacy testing.
Comprehensive portfolio for genotoxicity and skin sensitization assessments.
Full spectrum of preclinical toxicology studies using various species.
Formulation development and bioanalysis for clinical trial support.
Unlock access to complete
Unlock access to complete
Funding Insights of Scantox
Scantox has successfully raised a total of $6.29M across 2 strategic funding rounds. The most recent funding activity was a Unspecified round of $228.85 thousand completed in January 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Unspecified — $228,852
-
First Round
First Round
(18 Jan 2021)
- Investors Count Investors Count
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2022 | Amount | Unspecified - Scantox | Valuation |
investors |
|
| Jan, 2021 | Amount | Unspecified - Scantox | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investments & Acquisitions by Scantox
Scantox has strategically engaged in corporate development activities, having acquired 4 companies. Notable acquisitions include Adlego Biomedical, Gentronix and Q&Q Labs. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Drug R&D services for toxicology and histopathology are offered.
|
2013 | ||||
|
Leading provider of preclinical services for the pharmaceutical, biotech, and medical devices industries
|
2010 | ||||
|
In-vivo pharmacology and toxicology services are provided for drug candidates.
|
2005 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Scantox
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Scantox Comparisons
Competitors of Scantox
Scantox operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Charles River Laboratories, LabCorp, Cytel, Precision Medicine Group and Veeda Clinical Research, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Provider of drug discovery and preclinical development services
|
|
| domain | founded_year | HQ Location |
Provider of laboratory tests for physicians
|
|
| domain | founded_year | HQ Location |
Data analysis and statistical solutions are provided for life sciences.
|
|
| domain | founded_year | HQ Location |
Provider of clinical research, development, and commercialization services for life sciences
|
|
| domain | founded_year | HQ Location |
Drug development services encompassing clinical trials, bioanalytical support, and real-world evidence in healthcare.
|
|
| domain | founded_year | HQ Location |
Company offering specialised R&D and clinical development services for the development of precision medicine based drugs and devices
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Scantox
Frequently Asked Questions about Scantox
When was Scantox founded?
Scantox was founded in 1977 and raised its 1st funding round 44 years after it was founded.
Where is Scantox located?
Scantox is headquartered in Lille Skensved, Denmark.
Who is the current CEO of Scantox?
Jeanet Logsted is the current CEO of Scantox.
Is Scantox a funded company?
Scantox is a funded company, having raised a total of $6.29M across 2 funding rounds to date. The company's 1st funding round was a Unspecified of $6.06M, raised on Jan 18, 2021.
How many employees does Scantox have?
As of Nov 30, 2024, the latest employee count at Scantox is 30.
What is the annual revenue of Scantox?
Annual revenue of Scantox is $18.22M as on Dec 31, 2022.
What does Scantox do?
Scantox offers Discovery Services, Genetic Toxicology Services, Regulatory Toxicology Services, Pharmaceutical Development Services while focusing on providing healthcare solutions, biopharma outsourcing, cro, and diversified. Laboratory focused on providing pharmacology, toxicology, and histopathology services. Delivering reliable solutions, it emphasizes quality, efficiency, and meeting diverse client needs.
Who are the top competitors of Scantox?
Scantox's top competitors include LabCorp, Charles River Laboratories and Cytel.
What products or services does Scantox offer?
Scantox offers Discovery Services, Genetic Toxicology Services, Regulatory Toxicology Services, and Pharmaceutical Development Services.
How many acquisitions has Scantox made?
Scantox has made 4 acquisitions, including Adlego Biomedical, Gentronix, and Q&Q Labs.
What is Scantox's valuation?
The valuation of Scantox is $19.19M as of Jan 2022.